Fig. 4: The RBD-homodimer vaccination protected RMs from SARS-CoV-2 challenge. | Cell Discovery

Fig. 4: The RBD-homodimer vaccination protected RMs from SARS-CoV-2 challenge.

From: RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates

Fig. 4: The RBD-homodimer vaccination protected RMs from SARS-CoV-2 challenge.

a The experiment scheme. Four RMs were immunized via i.m. route with 25 µg or 50 µg of RBD vaccine at Day 0, 14, and 28, respectively. Four animals were injected with an equal volume of the adjuvant. At Day 42 of post-first shot, all the animals were challenged by SARS-CoV-2 (1.0 × 105 TCID50). Viral loads in swabs were monitored to evaluate viral replication kinetics in RMs. The viral RNA was extracted to quantify viral copies. b, c Bars indicated the GMT of anti-RBD specific IgG titers (b) and neutralizing antibody titers (c) of live SARS-CoV-2. d, e RNA copies of throat (d) and anal swabs (e) from each RM through the experiment course. f Viral RNA load in the upper, middle, and lower lung at the endpoint from vehicle, low-dose, and high-dose group. The data were presented as means ± SEM. g Pulmonary pathology detected by H&E staining. Scalar bars, 100 µm (10×).

Back to article page